Several interesting papers on breast cancer and hormone therapy will be presented at the American Society of Clinical Oncology’s annual meeting, starting June 3-7, 2011.
They include: *US research which found that past use of combined oral oestrogen and progesterone for more than 10 years was associated with persistently increased risk of invasive breast cancer, even after stopping hormone therapy.
Past use of hormone therapy and breast cancer risk. | 2011 ASCO Annual Meeting Abstracts
*A small Taiwanese study showing that many women with breast cancer receiving adjuvant hormone therapy have mild to moderate cognitive impairment.
Cognitive function and predictors for mild cognitive impairment in women receiving adjuvant hormone therapy. | 2011 ASCO Annual Meeting Abstracts
*An international study showing hormone replacement therapy after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers is not associated with an increased risk of breast cancer.
Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? | 2011 ASCO Annual Meeting Abstracts
In another recent study, published in Climacteric (online May 5, 2011), Belgian researchers were unable to find a strong association between a drop in breast cancer incidence and a decrease in hormone replacement therapy use.
Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium
Content updated 30 May 2011